Osiris Therapeutics, Inc. Reaches Safety Milestone In Stem Cell Clinical Trial For Cardiac Patients
Osiris Therapeutics, Inc. announced today that its multi-center, human clinical stem cell trial for the treatment of patients suffering from heart attacks has successfully passed the first safety milestone of the trial.
Article
Dendreon’s Second Randomized Phase 3 D9902A Trial of Provenge Extends Survival in Patients with Advanced Prostate Cancer
Dendreon Corporation (Nasdaq: DNDN) today announced that final results of its second Phase 3 study (D9902A) of PROVENGE(R) (sipuleucel-T), the Company’s investigational active cellular immunotherapy for the treatment of prostate cancer, were presented here today during a late-breaking clinical trials session at ECCO 13-the European Cancer Conference.
Article
Progenitor Cell Therapy Commences Expansion of Its Cell Therapy Manufacturing Facility in Mountain View, California
Progenitor Cell Therapy, LLC (PCT), a leading full service cell therapy development and contract manufacturing company, announced today that it has started construction on the next expansion phase of its cGMP/cGTP cell therapy manufacturing facility in Mountain View, California.
Article
CalbaTech, Inc.’s Subsidiary, LifeStem Inc. Files Provisional Patent Application For Stem Cell Microbank And To Trademark “Stem Cell Microbank”
CalbaTech, Inc., an emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., filed for US Trademark protection for the name of its stem cell collection service, Stem Cell Microbank, and filed a provisional patent application on the process of the Stem Cell Microbank for its process of stem cell banking.
Article
Endocyte Near Patent for Cancer Treatment Technology
The Purdue Research Park firm announced Wednesday that the U.S. Patent and Trademark Office has issued it a notice of allowance for a patent encompassing a proprietary treatment method that helps the immune system find and destroy cancer cells.
Article
Tissera Reports Encouraging Interim Results of Its Ongoing Large Animal Experiments of Pancreatic Xenotransplantation
Tissera, Inc. (OTCBB:TSSR) reports encouraging interim results of its ongoing large animal model experiments of pancreatic xenotransplantation, designed for the future treatment of insulin-dependent (type I) diabetes mellitus.
Article
BrainStorm Announces Significant Preclinical Benefit of Its GDNF Producing Stem Cells in Animal Models of Parkinson’s
BrainStorm Cell Therapeutics (OTCBB:BCLI), today announced that the company’s scientific collaborators at Tel Aviv University had successfully implanted human bone marrow derived stem cells into animal models of Parkinson’s disease and observed improved motor function within just two weeks of implantation.
Article
Cytori Therapeutics, Inc. Enters Strategic Regenerative Medicine Collaboration With Olympus Corporation
As part of the terms and agreements, the two companies will form a 50:50 Joint Venture, Olympus-Cytori, Inc., to develop and manufacture future generation devices based on Cytori’s Celutionâ„¢ System.
Article
Targeted Genetics Presents Additional Data from Its Inflammatory Arthritis Program at the 13th Annual Congress of the European Society of Gene Therapy
Results demonstrate safety and reduction of mean tenderness and swelling scores of the treated joint; results support continued study of tgAAC94 in conjunction with TNF-alpha antagonists in inflammatory arthritis
Article
Peregrine Pharmaceuticals Announces Defense Department Grant to Study Tarvacin(TM) Platform for Prostate Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM – News), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced the U.S. Department of Defense Prostate Cancer Research Program has awarded a grant totaling $582,988 to the University of Texas Southwestern Medical Center at Dallas to study the use of vascular targeting antibodies in combination with chemotherapy agents for the treatment of prostate cancer.
Article
Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.
Cambridge Antibody Technology today announces the acquisition of product candidates GCR-3888 and GCR-8015 from Genencor, a subsidiary of Danisco, based in Palo Alto, California.
Article
Stem Cell Sciences, Inc. Grants Lexicon Genetics Incorporated (LEXG) Exclusive License To IRES Technology
Lexicon Genetics Incorporated and Stem Cell Sciences plc (AIM: STEM) announced today a significant expansion related to Lexicon’s rights to SCS’s proprietary Internal Ribosome Entry Site (“IRES”) technology for genetically modified mice. IRES technology is commonly used to enhance the accuracy of gene expression in genetically altered mice and cultured stem cells.
Article
Oxford BioMedica Seeks £30m for Cancer Drug Trials
Oxford BioMedica, the speculative biotechnology company formed out of the Oxford University a decade ago, is talking to fund managers about a fund-raising to pay for large-scale trials of a cancer treatment.
Article
AnorMED To Commence Trading On AMEX
AnorMED Inc. (the “Company” or “AnorMED”) is pleased to announce that the United States Securities & Exchange Commission has declared the Company’s registration statement on Form 40-F effective on November 3, 2005.
Article
Albany Molecular Research, Inc. Opens New Facilities in Singapore and India
Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced that its wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte. Ltd. (AMRSRC), has moved into permanent laboratory facilities in Singapore that provide room for significant growth.
Article
Jonathan Lakey, Ph.D. Presents the Edmonton Protocol for Islet Cell Transplantation to the Sanguine Medical Advisory Board
The medical advisory board of Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion, received a presentation from Dr. Jonathan Lakey, the director of the Clinical Islet Laboratory at the University of Alberta at Edmonton related to the Edmonton Protocol, including the use of PHER-O2.
Article
Immucor (BLUD) To Close Its Houston Manufacturing Facility
Immucor, Inc. , the global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today it plans to close its Houston, Texas manufacturing facility.
Article
AssurX Announces Immediate Availability of CATSWeb Process for Document Control
AssurX, Inc., the leader in Enterprise Quality and Compliance Systems, today announced the immediate availability of CATSWeb Process for Document Control, allowing built-in, easy and effective management of the controlled content life cycle from change orders through release approval, dissemination and training.
Article
Cellerant Therapeutics, Inc. Appoints Ramkumar Mandalam As Vice President Of Pharmaceutical Operations
Cellerant Therapeutics, Inc. today announced that Ramkumar Mandalam, Ph.D., has joined Cellerant Therapeutics as Vice President of Pharmaceutical Operations.
Article